Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cord blood stem cells

J E Wagner1, J Kurtzberg

  • 1Pediatric Blood and Marrow Transplant Program, University of Minnesota, Minneapolis 55455, USA.

Current Opinion in Hematology
|November 14, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytomegalovirus-Specific Immunity Recovers More Slowly after Cord Blood Transplantation Compared with Matched Sibling Donor Allogeneic Transplantation.

Transplantation and cellular therapy·2021
Same author

Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy.

Science advances·2019
Same author

Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts.

The British journal of dermatology·2019
Same author

In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning.

Bone marrow transplantation·2016
Same author

Investigation of the 3-D actinic flux field in mountainous terrain.

Atmospheric research·2015
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Umbilical cord blood transplants show high engraftment rates and low graft-versus-host disease (GVHD) risk, even with HLA disparities. Cell dose and HLA match may influence survival in these stem cell therapies.

Area of Science:

  • Hematology
  • Immunology
  • Transplantation Medicine

Background:

  • Bone marrow transplant limitations include donor availability and immunologic complications like graft-versus-host disease (GVHD) and infection.
  • Umbilical cord blood (UCB) offers an alternative stem cell source, potentially overcoming some limitations of traditional bone marrow transplantation.

Purpose of the Study:

  • To evaluate the efficacy and safety of UCB transplantation for malignant and nonmalignant diseases.
  • To analyze factors influencing engraftment, GVHD, and survival in UCB transplant recipients.

Main Methods:

  • Retrospective analysis of over 450 patients transplanted with UCB from related and unrelated donors.
  • Comparison of outcomes based on donor type (sibling vs. unrelated) and HLA matching.

Related Experiment Videos

  • Statistical analysis including multiple regression to identify factors affecting survival and GVHD.

    • Main Results:

    • High engraftment rates (0.91-0.94) observed in both sibling and unrelated UCB recipients.
    • Low incidence of severe acute GVHD (0.01-0.10) and no reported extensive chronic GVHD.
    • Two-year survival rate of 0.40 for unrelated UCB recipients.
    • Cell dose and HLA mismatch were potential factors impacting survival.

    Conclusions:

    • UCB transplantation is a viable option with high engraftment and low GVHD risk, even with increased HLA disparity.
    • Further research into demographic, graft, and treatment factors is needed to optimize UCB transplant outcomes.